NEW YORK (GenomeWeb News) – Oxford Gene Technology has acquired protein array firm Sense Proteomic for an undisclosed sum.

UK-based Sense Proteomic has identified biomarker panels for a variety of diseases including prostate cancer and lupus. According to OGT, Sense Proteomic's technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and also can be used to monitor response to therapeutic interventions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.